ADVERSE REACTIONS SECTION
The following serious adverse reactions are described elsewhere in the labeling:
• Clinical Worsening and Suicide Risk [see Boxed Warning and Warnings and Precautions ]
• Serotonin Syndrome or NMS-Like Reactions [see Warnings and Precautions]
• QT Prolongation and Risk of Sudden Death [see Warnings and Precautions ]
• Orthostatic Hypotension [see Warnings and Precautions]
• Abnormal Bleeding Events [see Warnings and Precautions ]
• Priapism [see Warnings and Precautions]
• Hyponatremia [see Warnings and Precautions ]
• Cognitive and Motor Impairment [see Warnings and Precautions]
• Discontinuation Symptoms [see Warnings and Precautions ]
The most common adverse reactions (reported in ≥ 5% and at twice the rate of placebo) are:
Somnolence/sedation, dizziness, constipation, vision blurred.
Table 2 presents the summary of adverse events (AEs) leading to discontinuation of trazodone hydrochloride tablets treatment with an incidence of at least 1% and at least twice that for placebo.
Table 2: Adverse Reactions With Discontinuation as
Action Taken (≥ 1%) Incidence and Incidence 2x Placebo
|
Trazodone
N = 202 |
Somnolence/Sedation |
8 (4%) |
Dizziness |
7 (3.5%) |
Confusional state |
2 (1%) |
Coordination abnormal |
2 (1%) |
Headache |
2 (1%) |
Nausea |
2 (1%) |
Balance disorder/Gait disturbance |
2 (1%) |
6.1 Clinical Studies Experience
The table below is presented solely to indicate the relative frequency of adverse events reported in representative controlled clinical studies conducted to evaluate the safety and efficacy of trazodone hydrochloride.
The figures cited cannot be used to predict concisely the incidence of untoward events in the course of usual medical practice where patient characteristics and other factors often differ from those which prevailed in the clinical trials. These incidence figures, also, cannot be compared with those obtained from other clinical studies involving related drug products and placebo as each group of drug trials is conducted under a different set of conditions.
* Incidence less than 1% |
Table 3: Adverse Reactions: Percentage of Patients (> 2%) as Observed in Controlled Clinical Studies |
InpatientsOutpatients |
| Trazodone |
Placebo |
Trazodone |
Placebo |
Number of Patients |
142 |
95 |
157 |
158 |
% of Patients Reporting |
|
|
|
|
Allergic |
|
|
|
|
Skin Condition/Edema |
2.8 |
1.1 |
7 |
1.3 |
Autonomic |
|
|
|
|
Blurred Vision |
6.3 |
4.2 |
14.7 |
3.8 |
Constipation |
7 |
4.2 |
7.6 |
5.7 |
Dry Mouth |
14.8 |
8.4 |
33.8 |
20.3 |
Cardiovascular |
|
|
|
|
Hypertension |
2.1 |
1.1 |
1.3 |
*
|
Hypotension |
7 |
1.1 |
3.8 |
0 |
Shortness of Breath |
*
|
1.1 |
1.3 |
0 |
Syncope |
2.8 |
2.1 |
4.5 |
1.3 |
Tachycardia/Palpitations |
0 |
0 |
7 |
7 |
CNS |
|
|
|
|
Anger/Hostility |
3.5 |
6.3 |
1.3 |
2.5 |
Confusion |
4.9 |
0 |
5.7 |
7.6 |
Decreased Concentration |
2.8 |
2.1 |
1.3 |
0 |
Disorientation |
2.1 |
0 |
*
|
0 |
Dizziness/Light-Headedness |
19.7 |
5.3 |
28 |
15.2 |
Drowsiness |
23.9 |
6.3 |
40.8 |
19.6 |
Excitement |
1.1 |
1.1 |
5.1 |
5.7 |
Fatigue |
11.3 |
4.2 |
5.7 |
2.5 |
Headache |
9.9 |
5.3 |
19.8 |
15.8 |
Insomnia |
9.9 |
10.5 |
6.4 |
12 |
Impaired Memory |
1.4 |
0 |
*
|
*
|
Nervousness |
14.8 |
10.5 |
6.4 |
8.2 |
Gastrointestinal |
|
|
|
|
Abdominal/Gastric Disorder |
3.5 |
4.2 |
5.7 |
4.4 |
Bad Taste in Mouth |
1.4 |
0 |
0 |
0 |
Diarrhea |
0 |
1.1 |
4.5 |
1.9 |
Nausea/Vomiting |
9.9 |
1.1 |
12.7 |
9.5 |
Musculoskeletal |
|
|
|
|
Musculoskeletal Aches/Pains |
5.6 |
3.2 |
5.1 |
2.5 |
Neurological |
|
|
|
|
Incoordination |
4.9 |
0 |
1.9 |
0 |
Paresthesia |
1.4 |
0 |
0 |
*
|
Temors |
2.8 |
1.1 |
5.1 |
3.8 |
Sexual Function |
|
|
|
|
Decreased Libido |
*
|
1.1 |
1.3 |
*
|
Other |
|
|
|
|
Decreased Appetite |
3.5 |
5.3 |
0 |
*
|
Eyes Red/Tired/Itching |
2.8 |
0 |
0 |
0 |
Head Full-Heavy |
2.8 |
0 |
0 |
0 |
Malaise |
2.8 |
0 |
0 |
0 |
Nasal/Sinus Congestion |
2.8 |
0 |
5.7 |
3.2 |
Nightmares/Vivid Dreams |
*
|
1.1 |
5.1 |
5.7 |
Sweating/Clamminess |
1.4 |
1.1 |
*
|
*
|
Tinnitus |
1.4 |
0 |
0 |
*
|
Weight Gain |
1.4 |
0 |
4.5 |
1.9 |
Weight Loss |
*
|
3.2 |
5.7 |
2.5 |
Occasional sinus bradycardia has occurred in long-term studies.
In addition to the relatively common (i.e., greater than 1%) untoward events enumerated above, the following adverse events have been reported to occur in association with the use of trazodone hydrochloride in the controlled clinical studies: akathisia, allergic reaction, anemia, chest pain, delayed urine flow, early menses, flatulence, hallucinations/delusions, hematuria, hyper-salivation, hypomania, impaired speech, impotence, increased appetite, increased libido, increased urinary frequency, missed periods, muscle twitches, numbness, and retrograde ejaculation.
6.2 Postmarketing Experience
Spontaneous reports regarding trazodone hydrochloride received from postmarketing experience include the following: abnormal dreams, agitation, alopecia, anxiety, aphasia, apnea, ataxia, breast enlargement or engorgement, cardiospasm, cerebrovascular accident, chills, cholestasis, clitorism, congestive heart failure, diplopia, edema, extrapyramidal symptoms, grand mal seizures, hallucinations, hemolytic anemia, hirsutism, hyperbilirubinemia, increased amylase, increased salivation, insomnia, leukocytosis, leukonychia, jaundice, lactation, liver enzyme alterations, methemoglobinemia, nausea/vomiting (most frequently), paresthesia, paranoid reaction, priapism [see Warnings and Precautions and Patient Counseling Information], pruritus, psoriasis, psychosis, rash, stupor, inappropriate ADH syndrome, tardive dyskinesia, unexplained death, urinary incontinence, urinary retention, urticaria, vasodilation, vertigo, and weakness.
Cardiovascular system effects which have been reported include the following: conduction block, orthostatic hypotension and syncope, palpitations, bradycardia, atrial fibrillation, myocardial infarction, cardiac arrest, arrhythmia, ventricular ectopic activity, including ventricular tachycardia and QT prolongation. In postmarketing surveillance, prolonged QT interval, torsade de pointes, and ventricular tachycardia have been reported with the immediate-release form of trazodone at doses of 100 mg per day or less [see Warnings and Precautions].
|
REPORTS OF SUSPECTED TRAZODONE SIDE EFFECTS / ADVERSE REACTIONS
Below is a sample of reports where side effects / adverse reactions may be related to Trazodone. The information is not vetted and should not be considered as verified clinical evidence.
Possible Trazodone side effects / adverse reactions in 30 year old female
Reported by a physician from United States on 2011-12-22
Patient: 30 year old female
Reactions: Completed Suicide
Adverse event resulted in: death
Suspect drug(s):
Trazodone
Administration route: Oral
Venlafaxine HCL
Administration route: Oral
Possible Trazodone side effects / adverse reactions in 43 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-01-04
Patient: 43 year old female
Reactions: Death
Adverse event resulted in: death
Suspect drug(s):
Salicylates
Dosage: unknown
Start date: 2008-01-01
End date: 2008-01-01
Trazodone
Dosage: unknown
Start date: 2008-01-01
End date: 2008-01-01
Ibuprofen
Dosage: unknown
Start date: 2008-01-01
End date: 2008-01-01
Quetiapine
Dosage: unknown
Start date: 2008-01-01
End date: 2008-01-01
Possible Trazodone side effects / adverse reactions in 44 year old male
Reported by a physician from United States on 2012-04-16
Patient: 44 year old male
Reactions: Respiratory Arrest, Drug Abuse, Cardiac Arrest
Adverse event resulted in: death
Suspect drug(s):
Oxycodone Hydrochloride
Dosage: unk
Administration route: Oral
Mirtazapine
Dosage: unk
Administration route: Oral
Hydroxyzine Pamoate
Dosage: unk
Administration route: Oral
Trazodone
Dosage: unk
Administration route: Oral
|